The collaboration focuses on multiple research programmes designed to develop and commercialise site-specific recombinases for diseases characterised by severe unmet medical needs.
The company expects the facility to increase production capacity and improve supply chain responsiveness across the Middle East and Africa (MEA).
The project received financial backing from First City Monument Bank (FCMB) and the Bank of Industry (BoI), reflecting a coordinated push to support local industry growth.
The acquisition gives Lilly access to Ajax’s experimental therapies for myeloproliferative neoplasms (MPNs), a group of rare blood cancers in which the bone marrow produces excessive blood cells.
The acquisition is expected to strengthen Sun Pharma’s global footprint while broadening its presence in women’s health, biosimilars, and established medicines.
The US Food and Drug Administration granted the therapy Breakthrough Therapy Designation, while the European Medicines Agency awarded it Priority Medicines status.
The Slovenská Ľupča site will support Evonik’s contract development and manufacturing organization (CDMO) services within its drug substance business.
Spread across approximately 20,000 square metres, the plant is equipped with automated production lines and advanced quality control laboratories built to international pharmaceutical standards.
The Illinois-based drugmaker said the new campus will span 185 acres near Research Triangle Park, one of the country’s leading life sciences clusters.
The study showed that oral semaglutide achieved a significantly greater reduction in HbA1c levels, a key marker of blood sugar control, compared to placebo.